{"id":34126,"date":"2025-05-26T14:43:21","date_gmt":"2025-05-26T06:43:21","guid":{"rendered":"https:\/\/flcube.com\/?p=34126"},"modified":"2025-05-26T14:43:21","modified_gmt":"2025-05-26T06:43:21","slug":"duality-biologics-receives-fda-ind-approval-for-egfr-her3-adc-avzo-1418","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34126","title":{"rendered":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418"},"content":{"rendered":"\n

Duality Biologics (HKG: 9606<\/a>), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.<\/p>\n\n\n\n

AVZO-1418\/DB-1418 Mechanism<\/strong>
AVZO-1418\/DB-1418 is an EGFR\/HER3 dual-targeting ADC based on topoisomerase-1 inhibitors. It was developed using DualityBio\u2019s proprietary Duality Innovative Bispecific Antibody Conjugate (DIBAC) platform. Preclinical studies demonstrated higher binding affinity to tumor cells and efficacy across various solid tumors, including those resistant to EGFR or HER3.<\/p>\n\n\n\n

Licensing Agreement<\/strong>
In January of this year, US-based oncology-focused biotech Avenzo Therapeutics, Inc. entered into a licensing agreement with Duality Biologics. Avenzo acquired exclusive global development, manufacturing, and commercialization rights to AVZO-1418\/DB-1418, excluding Greater China.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United…<\/p>\n","protected":false},"author":1,"featured_media":34127,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[1721,232,3974],"class_list":["post-34126","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-avenzo-therapeutics","tag-duality-biologics","tag-hkg-9606"],"yoast_head":"\nDuality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418 - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34126\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418\" \/>\n<meta property=\"og:description\" content=\"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34126\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-26T06:43:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Duality Biologics Receives FDA IND Approval for EGFR\\\/HER3 ADC AVZO-1418\",\"datePublished\":\"2025-05-26T06:43:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126\"},\"wordCount\":155,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2610.webp\",\"keywords\":[\"Avenzo Therapeutics\",\"Duality Biologics\",\"HKG: 9606\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34126#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34126\",\"name\":\"Duality Biologics Receives FDA IND Approval for EGFR\\\/HER3 ADC AVZO-1418 - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2610.webp\",\"datePublished\":\"2025-05-26T06:43:21+00:00\",\"description\":\"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\\\/DB-1418. This potential best-in-class EGFR\\\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34126\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2610.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/05\\\/2610.webp\",\"width\":1080,\"height\":608,\"caption\":\"Duality Biologics Receives FDA IND Approval for EGFR\\\/HER3 ADC AVZO-1418\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34126#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Duality Biologics Receives FDA IND Approval for EGFR\\\/HER3 ADC AVZO-1418\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418 - Insight, China's Pharmaceutical Industry","description":"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34126","og_locale":"en_US","og_type":"article","og_title":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418","og_description":"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.","og_url":"https:\/\/flcube.com\/?p=34126","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-05-26T06:43:21+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34126#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34126"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418","datePublished":"2025-05-26T06:43:21+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34126"},"wordCount":155,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","keywords":["Avenzo Therapeutics","Duality Biologics","HKG: 9606"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34126#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34126","url":"https:\/\/flcube.com\/?p=34126","name":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418 - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34126#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34126#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","datePublished":"2025-05-26T06:43:21+00:00","description":"Duality Biologics (HKG: 9606), a developer of antibody conjugate drugs (ADCs) operating in the United States and China, announced that it has received Investigational New Drug (IND) approval from the US FDA for its AVZO-1418\/DB-1418. This potential best-in-class EGFR\/HER3 bispecific antibody conjugate drug (ADC) represents a significant advancement in oncology treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34126#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34126"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34126#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","width":1080,"height":608,"caption":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34126#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Duality Biologics Receives FDA IND Approval for EGFR\/HER3 ADC AVZO-1418"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/05\/2610.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34126","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34126"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34126\/revisions"}],"predecessor-version":[{"id":34128,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34126\/revisions\/34128"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34127"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34126"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34126"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34126"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}